Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects
Portfolio Pulse from Vandana Singh
Gilead Sciences Inc's (NASDAQ:GILD) blood cancer drug Magrolimab, acquired through a $4.9 billion buyout of Forty Seven Inc, has shown higher deaths and side effects in halted trials. The drug failed to meet primary endpoints in Phase 3 trials, leading to a negative market reaction.
June 17, 2024 | 4:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Gilead Sciences' blood cancer drug Magrolimab has shown higher deaths and side effects in halted trials, failing to meet primary endpoints. This has led to a negative market reaction, with shares down 0.95%.
The halted trials of Magrolimab, a key drug in Gilead's portfolio, showed higher deaths and side effects, failing to meet primary endpoints. This negative outcome has led to a decline in Gilead's stock price, reflecting investor concerns.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100